RAPT Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q3 2018 to Q2 2024

Taxonomy & unit: us-gaap: USD
Description: Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary: RAPT Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q3 2018 to Q2 2024.
RAPT Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $5.38M, a 27% increase year-over-year.
RAPT Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $19.5M, a 37.4% increase year-over-year.
RAPT Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $17.1M, a 51.7% increase from 2022.
RAPT Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $11.3M, a 13.2% increase from 2021.
RAPT Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $9.95M, a 14.6% increase from 2020.

Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)

Share-based Payment Arrangement, Expense, Quarterly (USD)

Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q2 2024	$19.5M	$5.38M	+$1.15M	+27%	Apr 1, 2024	Jun 30, 2024	10-Q	2024-08-08
Q1 2024	$18.4M	$5.4M	+$1.3M	+31.9%	Jan 1, 2024	Mar 31, 2024	10-Q	2024-05-09
Q4 2023	$17.1M	$4.43M	+$1.4M	+46.4%	Oct 1, 2023	Dec 31, 2023	10-K	2024-03-07
Q3 2023	$15.7M	$4.33M	+$1.46M	+51.1%	Jul 1, 2023	Sep 30, 2023	10-Q	2023-11-13
Q2 2023	$14.2M	$4.24M	+$1.57M	+58.6%	Apr 1, 2023	Jun 30, 2023	10-Q	2024-08-08
Q1 2023	$12.7M	$4.09M	+$1.39M	+51.5%	Jan 1, 2023	Mar 31, 2023	10-Q	2024-05-09
Q4 2022	$11.3M	$3.03M	+$653K	+27.5%	Oct 1, 2022	Dec 31, 2022	10-K	2024-03-07
Q3 2022	$10.6M	$2.87M	+$860K	+42.9%	Jul 1, 2022	Sep 30, 2022	10-Q	2023-11-13
Q2 2022	$9.75M	$2.67M	-$216K	-7.48%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-08-11
Q1 2022	$9.97M	$2.7M	+$15K	+0.56%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-11
Q4 2021	$9.95M	$2.37M	-$186K	-7.27%	Oct 1, 2021	Dec 31, 2021	10-K	2023-03-14
Q3 2021	$10.1M	$2.01M	$0	0%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-10
Q2 2021	$10.1M	$2.89M	+$853K	+41.9%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-11
Q1 2021	$9.29M	$2.69M	+$599K	+28.7%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-11
Q4 2020	$8.69M	$2.56M	+$1.66M	+185%	Oct 1, 2020	Dec 31, 2020	10-K	2022-03-10
Q3 2020	$7.02M	$2.01M	+$1.57M	+365%	Jul 1, 2020	Sep 30, 2020	10-Q	2021-11-10
Q2 2020	$5.45M	$2.04M	+$1.69M	+486%	Apr 1, 2020	Jun 30, 2020	10-Q	2021-08-11
Q1 2020	$3.76M	$2.09M	+$1.71M	+454%	Jan 1, 2020	Mar 31, 2020	10-Q	2021-05-11
Q4 2019	$2.05M	$896K			Oct 1, 2019	Dec 31, 2019	10-K	2021-03-11
Q3 2019		$431K	+$136K	+46.1%	Jul 1, 2019	Sep 30, 2019	10-Q	2020-11-16
Q2 2019		$347K			Apr 1, 2019	Jun 30, 2019	10-Q	2020-08-13
Q1 2019		$377K			Jan 1, 2019	Mar 31, 2019	10-Q	2020-05-14
Q3 2018		$295K			Jul 1, 2018	Sep 30, 2018	10-Q	2019-12-11

* An asterisk sign (*) next to the value indicates that the value is likely invalid.